ClinicalTrials.gg
CompletedNCT01928147Updated Nov 26, 2015

A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients

A Phase 1 interventional study of PPI-383 and Placebo in Hepatitis C, Chronic, sponsored by Presidio Pharmaceuticals, Inc.. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-26.

Sponsored by Presidio Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies in Hepatitis C, Chronic with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · United Kingdom.

Enrollment
41st of 55
114 · median 334
Started
2013
with 5 others
Phase 1
Only one
of the 64
Registered
46th of 64
by date

Among the 64 studies in Hepatitis C, Chronic with a site in United Kingdom, this one is the 41st largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2013, is the only one in phase 1, and was the 46th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 64 studies in Hepatitis C, Chronic with a site in United Kingdom is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 64 studies in Hepatitis C, Chronic with a site in United Kingdom as a file.
02

Study summary

PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection. This study is being done to assess the dose-related safety and tolerance of PPI-383 when given to healthy volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3 days (Part II). In addition, the study will assess how much PPI-383 is absorbed into the bloodstream. In Part II, the dose-related effect of PPI-383 on the amount of hepatitis C virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • NS5B polymerase inhibitor
  • Phase 1
  • Genotype 1
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part I volunteers (single and multiple dose) - key inclusion criteria

  • Healthy males
  • Age 18 to 55 years
  • (BMI)18 to 32 kg/m2

Part II patients- key inclusion criteria

  • Males, or females of non-
  • Age 18 to 65 years
  • Chronic , and absence of other known liver disease
  • Seropositive for HCV antibody (HCV Ab) or HCV RNA at least once previously
  • Seropositive for HCV Ab at screening
  • Serum HCV RNA > 5 log10 IU/mL at screening
  • HCV gt-1
  • Treatment-naïve for hepatitis C:
  • BMI 18 to 35 kg/m2
  • Otherwise in good health, without severe or chronic or recurrent conditions requiring frequent medical intervention or continual pharmacologic management, except for anti-hypertensive use
  • No medical or psychosocial conditions that would potentially interfere with the subject's ability to comply with the study assessments or visit schedule.

Part II patients - key exclusion criteria

  • Seropositive for (HIV) antibody or virus (HBV) surface antigen (HBsAg)
  • Signs or symptoms of decompensated liver disease
  • Evidence of cirrhosis or hepatocellular carcinoma
  • Diabetes Mellitus treated with insulin or hypoglycemic agents
  • Asthma requiring hospital admission within the preceding 12 months
  • History of alcohol abuse or illicit drug use which could interfere with a patient's compliance with the protocol requirements
  • Any of the following laboratory values at screening

    • (Hgb) \<11 g/dL in women or 12 g/dL in men
    • White blood cell count \<4,000/mm3
    • (ANC) \< 1800 per mm3
    • count \<100,000 per mm3
    • Serum creatinine > (ULN) at the central study laboratory
    • Serum albumin \<3.4 g/dL
    • Total >2.0 mg/dL
  • Clinically significant abnormality in the (ECGs) at screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    PPI-383 single dose escalation in healthy volunteers

    There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.

    Drug: PPI-383 · Drug: Placebo

  • Experimental
    PPI-383 multiple doses in healthy volunteers

    Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens

    Drug: PPI-383 · Drug: Placebo

  • Experimental
    PPI-383 multiple dose escalation in HCV Subjects

    Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients

    Drug: PPI-383 · Drug: Placebo

Interventions

  • DrugPPI-383
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Safety and tolerability, as measured by clinical adverse events and laboratory assessments

    Time frame: Part I, up to day 12; and Part II, up to day 17

Secondary outcomes

  1. PPI-383 plasma levels

    Time frame: Part I, up to day 12; and Part II, up to day 17

  2. serum HCV RNA levels

    Time frame: Part II, up to day 17

07

Study locations

6 sites
  • Investigational site
    Phoenix, Mauritius
  • Investigational site
    London, NW3 2QG, United Kingdom
  • Investigational site
    London, SE5 9RS, United Kingdom
  • Investigational site
    London, UE1 2AD, United Kingdom
  • Investigational site
    London, W2 1NY, United Kingdom
  • Investigational site
    Nottingham, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Jul 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2013
First posted
Aug 23, 2013
Start
Aug 2013
Primary completionActual
Jul 2015
CompletionActual
Nov 2015
Last update
Nov 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01928147
Lead sponsor
Presidio Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 23, 2013
Start date
Aug 2013
Primary completion
Jul 2015
Completion
Nov 2015
Last update
Nov 26, 2015

Study contacts

Nathaniel Brown, M.D.
study director · Presidio Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion